MEI Pharma Inc stock (US5846882069): following ticker change to LITS after reverse stock split

After completing a 1-for-25 reverse stock split on 09/09/2025 and a subsequent ticker change from MEIP to LITS on the Nasdaq Capital Market, MEI Pharma is now trading in the United States under the Lite Strategy name, marking a new chapter for the San Diego-based oncology company according to a corporate actions tracker updated on 09/10/2025 by Robinhood and related exchange notices.

The stock continues to reflect trading in the U.S. market, where the primary listing remains on Nasdaq in USD, and where the company historically focused on the development of oncology drug candidates for patients with cancer, a positioning that persists under the Lite Strategy identity as described in recent market profiles of the LITS listing.

As of: 02/06/2026

By the editorial team - specialized in equity coverage.

MEI Pharma Inc: core business model

MEI Pharma pursues a focused biotechnology model in which it advances clinical-stage oncology candidates and seeks value through regulatory milestones, potential approvals, and collaboration agreements in cancer treatment.

Recent corporate actions

Corporate action records and brokerage notices show that MEI Pharma executed a 1-for-25 reverse stock split effective 09/09/2025, consolidating every 25 shares of MEIP into one share in order to comply with listing standards on the Nasdaq Capital Market and to adjust the per-share trading price.

Immediately following this reverse split, the company implemented a ticker change from MEIP to LITS, with Robinhood and other trading platforms flagging the change as effective on 09/10/2025, while the underlying equity continued to trade on Nasdaq under the Lite Strategy, Inc. name.

The reverse stock split did not alter the overall market capitalization on the effective date, as the corporate action proportionally reduced the number of outstanding shares while increasing the share price, a standard mechanism used by development-stage biotechnology issuers to maintain exchange compliance.

Latest quarterly results for MEI Pharma Inc at a glance

Although MEI Pharma has transitioned to trading under the Lite Strategy ticker LITS, the company remains a development-stage oncology-focused issuer without large-scale commercial revenue, and recent descriptions of the business emphasize its clinical programs rather than material product sales.

Market data providers summarizing the latest available financial profile for Lite Strategy indicate that the company continues to operate without substantial recurring revenue while incurring research and development expenses as it advances its oncology pipeline, a pattern that is typical for early- to mid-stage biotechnology companies that have not yet brought a therapy to market.

Conclusion

The 1-for-25 reverse stock split in September 2025 and the subsequent Nasdaq ticker change from MEIP to LITS have reshaped how MEI Pharma is presented in U.S. equity markets, even as the underlying business retains its focus on oncology drug development.

With the company now trading as Lite Strategy on Nasdaq, investors tracking the stock in the United States will continue to monitor both the capital markets impact of the corporate actions and the progress of the clinical pipeline that underpins the issuers long-term potential in cancer therapeutics.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.